Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Rotigotine in RLS
NCT01562743Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2008
- Primary completion
- Oct 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rotigotine in restless legs syndrome (RLS), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Incidence and Severity of Adverse Events up to 54 weeks, Augmentation up to 53 weeks and 1 more. Started Aug 2008; status: completed.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT01562743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562743.